BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 3028596)

  • 1. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial.
    Havemann K; Wolf M; Holle R; Gropp C; Drings P; Manke HG; Hans K; Schroeder M; Heim M; Victor N
    Cancer; 1987 Mar; 59(6):1072-82. PubMed ID: 3028596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA; Bacchi M; Hürny C; Bernhard J; Cerny T; Martinelli G; Leyvraz S; Senn HJ; Stahel R; Siegenthaler P
    Ann Oncol; 1995 Feb; 6(2):157-66. PubMed ID: 7786823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients.
    Wolf M; Pritsch M; Drings P; Hans K; Schroeder M; Flechtner H; Heim M; Hruska D; Mende S; Becker H
    J Clin Oncol; 1991 Apr; 9(4):614-24. PubMed ID: 1648598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA; Alberto P; Hürny C; Bacchi M; Leyvraz S; Thürlimann B; Cerny T; Martinelli G; Stahel R; Ludwig C
    Ann Oncol; 1995 Jan; 6(1):41-8. PubMed ID: 7536028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA; Alberto P; Bleher EA; Ludwig C; Siegenthaler P; Martinelli G; Sauter C; Schatzmann E; Senn HJ
    Ann Oncol; 1994 Dec; 5(10):921-8. PubMed ID: 7696164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, adriamycin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alone in complete responders following VAPE induction and late intensification.
    Broder LE; Sridhar KS; Selawry OS; Charyulu KN; Rao RK; Saldana MJ; Donnelly EJ; Raub WA
    Am J Clin Oncol; 1994 Dec; 17(6):527-37. PubMed ID: 7977175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
    Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M
    Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of response to the first cycle of chemotherapy in small cell lung cancer. Results of a multicenter German trial.
    Wolf M; Havemann K; Holle R; Harms V; Drings P; Hans K; Dombrowski H; Victor N
    Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1197-205. PubMed ID: 2443363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.
    Evans WK; Feld R; Murray N; Pater J; Shelley W; Willan A; Osoba D; Levitt M; Coy P; Hodson I
    Semin Oncol; 1986 Sep; 13(3 Suppl 3):10-6. PubMed ID: 3020692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy.
    Gridelli C; Contegiacomo A; Lauria R; Gentile M; Airoma G; De Placido S; Perrone F; Ferrante G; Bianco AR
    Tumori; 1991 Dec; 77(6):506-10. PubMed ID: 1666468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
    Souhami RL; Rudd R; Ruiz de Elvira MC; James L; Gower N; Harper PG; Tobias JS; Partridge MR; Davison AG; Trask C
    J Clin Oncol; 1994 Sep; 12(9):1806-13. PubMed ID: 8083704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. 'Petites Cellules' Group.
    Urban T; Baleyte T; Chastang CL; Jeannin L; Delaval P; Zaegel M; Mornet M; Coetmeur D; Lebeau B
    Lung Cancer; 1999 Aug; 25(2):105-13. PubMed ID: 10470844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs.
    Daniels JR; Chak LY; Sikic BI; Lockbaum P; Kohler M; Carter SK; Reynolds R; Bohnen R; Gandara D; Yu J
    J Clin Oncol; 1984 Nov; 2(11):1192-9. PubMed ID: 6092554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
    J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group.
    Ettinger DS; Finkelstein DM; Abeloff MD; Ruckdeschel JC; Aisner SC; Eggleston JC
    J Clin Oncol; 1990 Feb; 8(2):230-40. PubMed ID: 2153765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.
    Feld R; Evans WK; Coy P; Hodson I; MacDonald AS; Osoba D; Payne D; Shelley W; Pater JL
    J Clin Oncol; 1987 Sep; 5(9):1401-9. PubMed ID: 3040923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
    Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.